A CRA team led by VP Raphaël De Coninck provided economic advice and support to Mylan for its merger with Pfizer’s Upjohn division, which operates Pfizer’s established generic and off-patent branded medicines (including products sold under the brands Viagra, Xanax and Lipitor). The merger was cleared in phase 1 by the European Commission, subject to a number of divestments.